Shire PLC (NASDAQ:SHPG) has been assigned a $213.00 price target by investment analysts at Royal Bank Of Canada in a research report issued on Friday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target points to a potential upside of 36.62% from the stock’s current price.

Several other research firms have also recently commented on SHPG. Sanford C. Bernstein restated a “market perform” rating and set a $210.00 price target on shares of Shire PLC in a research note on Thursday, July 13th. HSBC Holdings plc upgraded Shire PLC from a “reduce” rating to a “hold” rating in a research note on Thursday, July 6th. Jefferies Group LLC restated a “buy” rating and set a $216.00 price target (down previously from $239.00) on shares of Shire PLC in a research note on Friday, June 9th. Stifel Nicolaus cut their price target on Shire PLC from $250.00 to $245.00 and set a “buy” rating for the company in a research note on Friday, June 9th. Finally, Goldman Sachs Group, Inc. (The) restated a “conviction-buy” rating on shares of Shire PLC in a research note on Friday, April 14th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and sixteen have given a buy rating to the stock. Shire PLC presently has an average rating of “Buy” and a consensus target price of $223.18.

Shares of Shire PLC (NASDAQ:SHPG) traded down 3.51% during midday trading on Friday, hitting $155.91. 2,263,388 shares of the stock were exchanged. Shire PLC has a one year low of $155.06 and a one year high of $209.22. The firm has a market cap of $46.44 billion, a PE ratio of 159.91 and a beta of 1.60.

Shire PLC (NASDAQ:SHPG) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $3.73 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.53 by $0.20. Shire PLC had a return on equity of 14.32% and a net margin of 4.70%. The business had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.73 billion. During the same quarter in the prior year, the business earned $3.38 earnings per share. The company’s quarterly revenue was up 54.2% compared to the same quarter last year. On average, equities analysts predict that Shire PLC will post $14.88 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/08/06/shire-plc-shpg-given-a-213-00-price-target-by-royal-bank-of-canada-analysts.html.

A number of hedge funds have recently bought and sold shares of SHPG. HPM Partners LLC purchased a new stake in Shire PLC during the first quarter valued at $1,534,000. Vanguard Group Inc. increased its stake in shares of Shire PLC by 0.9% in the first quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock valued at $268,773,000 after buying an additional 13,665 shares in the last quarter. Laurion Capital Management LP bought a new stake in shares of Shire PLC during the first quarter valued at about $10,611,000. BlackRock Inc. increased its stake in shares of Shire PLC by 4,217.7% in the first quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock valued at $249,755,000 after buying an additional 1,400,275 shares in the last quarter. Finally, Gabelli Funds LLC increased its stake in shares of Shire PLC by 1,000.0% in the first quarter. Gabelli Funds LLC now owns 16,500 shares of the biopharmaceutical company’s stock valued at $2,875,000 after buying an additional 15,000 shares in the last quarter. 21.05% of the stock is currently owned by institutional investors.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.